Closing Bell: GoodRx Surges, Opendoor Rallies, Intel Slips

On this episode of Stock Movers: 

Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick,  Scarlet Fu, Tim Stenovec and Emily Graffeo.

- GoodRx (GDRX) shares soared as much as 37%, the biggest intraday jump since July 2023, on news Novo Nordisk is slashing the cost of Ozempic and partnering with GoodRx to offer it at US pharmacies.

- Opendoor (OPEN) shares rallied again, extending a three-day winning streak of about 60%, as retail traders continue buying. A plunge in the stock price had put the company at a risk of delisting. But last month, Canadian hedge fund manager Eric Jackson at EMJ Capital made a series of posts online laying out a bull case for the stock, leading to a surge. 

- Intel (INTC) shares slipped today on word that the Trump administration is considering a stake of about 10% in the beleaguered chipmaker. The federal government is considering a potential investment in Intel that would involve converting some or all of the company’s grants from the US Chips and Science Act into equity, said the people, who asked not to be identified because the information is confidential. Intel has been slated to receive a combined $10.9 billion in Chips Act grants for commercial and military production.

See omnystudio.com/listener for privacy information.